Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is taking immunotherapy to the next level in the fight against cancer and infectious diseases. They are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

Expert Comments:

Inovio Pharmaceuticals Inc. (INO:NASDAQ) has expanded the Phase 1 trial of its Ebola vaccine to include an additional 125 healthy subjects. This, according to Maxim Group analyst Jason Kolbert, will help the company determine an "optimal" strategy for intradermal (skin) vaccination.
read more >
Jason Kolbert, Maxim Group (8/11/16)
"Inovio Pharmaceuticals Inc. announced that the phase I study of INO-4212 (Ebola vaccine) in healthy subjects will expand to include 125 more subjects to determine the best immunization strategy using intradermal vaccination. . .intradermal administration has been shown in several Inovio studies to be more effective at driving antigen-specific antibody responses. Antibodies are critical for clearing viral infections as they bind to and neutralize viral particles in the circulation, as well as viral antigens on infected cells to either kill them directly or label them for other immune cells to come in and kill them."

Ram Selvaraju, Rodman & Renshaw (8/9/16)
"Inovio Pharmaceuticals Inc. reported its Q2/16 financial results. Total revenue was $6.2M, beating our projection, due to an increase in development payments from the company’s DARPA Ebola grant. . .importantly, management has indicated that both the FDA and the European Medicines Agency (EMA) have provided an affirmative path for VGX-3100 to treat HPV-16/18-related high-grade cervical dysplasia in a pivotal Phase 3 registration study. . .This is encouraging news, in our view."

Charles Duncan, Piper Jaffray & Co. (8/8/16)
"Inovio Pharmaceuticals Inc [ended] the quarter with $134.5M in cash. We project this cash will fund pipeline progress through 1H18, inclusive of significant progress on the soon-to-start Phase 3 in cervical dysplasia and advancement to late-stage trials for a broadening set of infectious disease and oncology programs including Zika, MERS, cervical cancer (with MedImmune), and potentially other tumors. . .in advance of increasingly visible clinical progress expected across the platform over the next 12 months, we reiterate OW [overweight rating]."

Charles Duncan, Piper Jaffray & Co. (7/15/16)
"We remain encouraged, specifically, for the correlation between in vivo generation of antigen-specific CD8+ T-Cells and clinical response, observed in the Phase IIb trial with VGX-3100 in CD. . .this study has informed Phase III plans, as well as a cervical cancer trial start for MedImmune-partnered INO-3112, both possible in 2016. We also recognize Inovio’s platform versus competitors' for quick and efficacious response to infectious disease outbreaks, evidenced by Inovio being the only company cleared to initiate a Phase I human study with its Zika vaccine by YE16. Ahead of progress in oncology and infectious disease."

Ram Selvaraju, H.C. Wainwright & Co. (6/21/16)
"Inovio Pharmaceuticals Inc. and its collaborator, GeneOne Life Science, disclosed that the FDA granted approval of the company’s IND to initiate a Phase 1 trial of its Zika virus DNA vaccine (GLS-5700). . .phase 1 study, scheduled to enroll 40 healthy subjects, is the first-ever human trial of a preventive vaccine targeting the Zika virus. . .GLS-5700 is likely to show similar safety attributes in this upcoming study. Inovio has sufficient capital to finish the study, and management expects to report results from the Phase 1 trial by the end of 2016."

Biotech Research Group, Seeking Alpha (6/21/16)
"Inovio Pharmaceuticals Inc. has the ability to respond quickly to these mutations utilizing a proprietary DNA based sequencing model designed to target and treat specific areas of cancer and infectious disease. . .Inovio is the only immunotherapy company that has reported generating t-cells "in vivo" in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. . .the next six months will be a busy period for investors to digest, with several data sets slated for public dissemination. . .an investment in the long-term future for Inovio is a solid investment choice.

Charles Duncan
Recent news from Inovio Pharmaceuticals Inc., a small-cap biotech developing immunotherapeutic vaccines that target cancer and infectious diseases like news-making viruses Ebola and Zika, has prompted Piper Jaffray analyst Charles Duncan to reiterate his thesis for investment in the company.
read more >

More Expert Comments

Experts Following This Company

Larry Biegelsen – Wells Fargo Securities
Jim Birchenough – BMO Capital Markets
Yi Chen, Managing Director of Equity Research – Rodman & Renshaw
Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Dorman Followwill, Partner and Director EIA – Frost & Sullivan Inc
Jason Kolbert, Senior Analyst – Maxim Group
Chen Lin What Is Chen Buying? What Is Chen Selling?
Jason McCarthy, Analyst – Maxim Group
Kevin McCarthy, Co-Managing Partner – Kayne Anderson MLP Investment Co.
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw

The information provided above is from analysts, newsletters, the company and other contributors.

Inovio Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Inovio Pharmaceuticals Inc. Content